, Volume 41, Issue 6, pp 1089–1095 | Cite as

Risk factors for false-negative results of T-SPOT.TB and tuberculin skin test in extrapulmonary tuberculosis

  • Y.-M. Lee
  • K.-H. Park
  • S.-M. Kim
  • S. J. Park
  • S.-O. Lee
  • S.-H. Choi
  • Y. S. Kim
  • J. H. Woo
  • S.-H. Kim
Clinical and Epidemiological Study



T-SPOT.TB, a recently developed T cell-based assay, has shown promise in diagnosing extrapulmonary tuberculosis (EPTB). However, a limited number of reports have compared the risk factors for false-negative results of tuberculin skin tests (TSTs) and T-SPOT.TB assays in patients with EPTB. We, thus, conducted a prospective, blinded, observational study to evaluate the risk factors for false-negative T-SPOT.TB and TST results in patients with EPTB.


Between April 2008 and November 2011, all adult patients with suspected EPTB were prospectively enrolled at Asan Medical Center, Seoul, South Korea (an intermediate TB-burden country). Only patients with confirmed and probable EPTB who underwent TST and T-SPOT.TB were included in the final analysis.


Of the 324 patients who underwent both TST and T-SPOT.TB testing, 128 patients with 96 (75 %) culture- or polymerase chain reaction (PCR)-confirmed and 32 (25 %) probable EPTB were finally analyzed. T-SPOT.TB assays were less likely to yield false-negative results than TSTs [17 % (22/128) vs. 54 % (69/128), p < 0.001]. In a multivariate analysis, miliary TB was associated with false-negative TSTs [odds ratio (OR) = 5.3; 95 % confidence interval (CI) 1.7–16.1], while immunosuppression showed a trend toward false-negative TSTs (OR = 2.5; 95 % CI 0.9–6.8). Conversely, lymph node TB (OR = 0.2; 95 % CI 0.1–0.5) and skeletal TB (OR = 0.2; 95 % CI 0.1–0.5) were associated with true-positive TST results. The only risk factor for false-negative T-SPOT.TB results was TB meningitis (OR = 2.6; 95 % CI 1.0–6.6).


Our findings suggest that T-SPOT.TB has a better sensitivity to diagnose EPTB than TST, especially in patients with immunosuppression or miliary TB.


T-SPOT.TB assay Tuberculin skin test False-negative results Risk factor 



We thank Professor Jung Bok Lee for reviewing the statistical methods used in our study. This study was supported by the Basic Science Research Program of the National Research Foundation funded by the Ministry of Education, Science and Technology (grant 2010-0005898).

Conflict of interest

There are no potential conflicts of interest.

Supplementary material

15010_2013_478_MOESM1_ESM.docx (23 kb)
Supplementary material 1 (DOCX 20 kb)


  1. 1.
    Cho OH, Park KH, Kim SM, Park SJ, Moon SM, Chong YP, et al. Diagnostic performance of T-SPOT.TB for extrapulmonary tuberculosis according to the site of infection. J Infect. 2011;63:362–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep. 2010;59:1–25.PubMedGoogle Scholar
  3. 3.
    Nash DR, Douglass JE. Anergy in active pulmonary tuberculosis. A comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses. Chest. 1980;77:32–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Holden M, Dubin MR, Diamond PH. Frequency of negative intermediate-strength tuberculin sensitivity in patients with active tuberculosis. N Engl J Med. 1971;285:1506–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest. 2010;137:952–68.PubMedCrossRefGoogle Scholar
  6. 6.
    Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB, et al. Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2011;37:100–11.PubMedCrossRefGoogle Scholar
  7. 7.
    Lee YM, Kim SM, Park SJ, Park KH, Lee SO, Choi SH, et al. Indeterminate T-SPOT.TB test results in patients with suspected extrapulmonary tuberculosis in routine clinical practice. Infect Chemother. 2013;45:44–50.CrossRefGoogle Scholar
  8. 8.
    Cho CH, Han SH, Chin BS, Choi SH, Lee HS, Kim CO, et al. Diagnosis and species identification of mycobacterial infections by polymerase chain reaction–restriction fragment length polymorphism analysis of sterile body fluids. Korean J Intern Med. 2009;24:135–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Kim SH, Choi SJ, Kim HB, Kim NJ, Oh MD, Choe KW. Diagnostic usefulness of a T-cell based assay for extrapulmonary tuberculosis. Arch Intern Med. 2007;167:2255–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Kim SH, Song KH, Choi SJ, Kim HB, Kim NJ, Oh MD, et al. Diagnostic usefulness of a T-cell-based assay for extrapulmonary tuberculosis in immunocompromised patients. Am J Med. 2009;122:189–95.PubMedCrossRefGoogle Scholar
  11. 11.
    Kim SH, Cho OH, Park SJ, Lee EM, Kim MN, Lee SO, et al. Rapid diagnosis of tuberculous meningitis by T cell-based assays on peripheral blood and cerebrospinal fluid mononuclear cells. Clin Infect Dis. 2010;50:1349–58.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee YM, Park KH, Kim SM, Park SJ, Lee SO, Choi SH, et al. Diagnostic usefulness of a T-cell-based assay in patients with miliary tuberculosis compared with those with lymph node tuberculosis. Clin Infect Dis. 2013;56:e26–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Marais S, Thwaites G, Schoeman JF, Török ME, Misra UK, Prasad K, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010;10:803–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA. 2005;293:2756–61.PubMedCrossRefGoogle Scholar
  15. 15.
    Simsek H, Alpar S, Ucar N, Aksu F, Ceyhan I, Gözalan A, et al. Comparison of tuberculin skin testing and T-SPOT.TB for diagnosis of latent and active tuberculosis. Jpn J Infect Dis. 2010;63:99–102.PubMedGoogle Scholar
  16. 16.
    Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4:761–76.PubMedCrossRefGoogle Scholar
  17. 17.
    Liao CH, Lai CC, Tan CK, Chou CH, Hsu HL, Tasi TH, et al. False-negative results by enzyme-linked immunospot assay for interferon-gamma among patients with culture-confirmed tuberculosis. J Infect. 2009;59:421–3.PubMedCrossRefGoogle Scholar
  18. 18.
    Ak O, Dabak G, Ozer S, Saygi A, Dabak R. The evaluation of the Quantiferon-TB Gold test in pulmonary and extrapulmonary tuberculosis. Jpn J Infect Dis. 2009;62:149–51.PubMedGoogle Scholar
  19. 19.
    Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, Dascher CC, et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest. 2000;105:1317–25.PubMedCrossRefGoogle Scholar
  20. 20.
    Girard JP, Paychère M, Cuevas M, Fernandes B. Cell-mediated immunity in an ageing population. Clin Exp Immunol. 1977;27:85–91.PubMedGoogle Scholar
  21. 21.
    Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis. 2005;5:415–30.PubMedCrossRefGoogle Scholar
  22. 22.
    Hillinger SM, Herzig GP. Impaired cell-mediated immunity in Hodgkin’s disease mediated by suppressor lymphocytes and monocytes. J Clin Invest. 1978;61:1620–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Pesanti EL. The negative tuberculin test. Tuberculin, HIV, and anergy panels. Am J Respir Crit Care Med. 1994;149:1699–709.PubMedCrossRefGoogle Scholar
  24. 24.
    Aydoğan O, Gürgün A, Başoğlu OK, Aşçi G, Ertilav M, Bacakoğlu F, et al. Tuberculin skin test reactivity in patients with chronic renal failure. Tuberk Toraks. 2009;57:268–76.PubMedGoogle Scholar
  25. 25.
    Starr S, Berkovich S. Effects of measles, gamma-globulin-modified measles and vaccine measles on the tuberculin test. N Engl J Med. 1964;270:386–91.PubMedCrossRefGoogle Scholar
  26. 26.
    Borgström E, Andersen P, Atterfelt F, Julander I, Källenius G, Maeurer M, et al. Immune responses to ESAT-6 and CFP-10 by FASCIA and multiplex technology for diagnosis of M. tuberculosis infection; IP-10 is a promising marker. PLoS One. 2012;7:e43438.PubMedCrossRefGoogle Scholar
  27. 27.
    Kobashi Y, Shimizu H, Ohue Y, Mouri K, Obase Y, Miyashita N, et al. False negative results of QuantiFERON TB-2G test in patients with active tuberculosis. Jpn J Infect Dis. 2009;62:300–2.PubMedGoogle Scholar
  28. 28.
    Mazurek GH, Weis SE, Moonan PK, Daley CL, Bernardo J, Lardizabal AA, et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis. 2007;45:837–45.PubMedCrossRefGoogle Scholar
  29. 29.
    Chee CB, Gan SH, Khinmar KW, Barkham TM, Koh CK, Liang S, et al. Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. J Clin Microbiol. 2008;46:1935–40.PubMedCrossRefGoogle Scholar
  30. 30.
    Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J. 2006;28:24–30.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Y.-M. Lee
    • 1
    • 2
  • K.-H. Park
    • 1
  • S.-M. Kim
    • 1
  • S. J. Park
    • 1
  • S.-O. Lee
    • 1
  • S.-H. Choi
    • 1
  • Y. S. Kim
    • 1
  • J. H. Woo
    • 1
  • S.-H. Kim
    • 1
  1. 1.Department of Infectious Diseases, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulRepublic of Korea
  2. 2.Department of Infectious Diseases, Busan Paik HospitalInje University College of MedicineBusanSouth Korea

Personalised recommendations